An MCP server that enables access to clinical evidence from the CIViC database, allowing users to search across variants, diseases, drugs, and phenotypes to support precision oncology research.
Nexonco by Nexgene Research is an MCP server for accessing clinical evidence from the CIViC (Clinical Interpretation of Variants in Cancer) database. It enables fast, flexible search across variants, diseases, drugs, and phenotypes to support precision oncology.
https://github.com/user-attachments/assets/02129685-5ba5-4b90-89e7-9d4a39986210
Watch full video here:
For detailed setup instructions, refer to the following documentation:
NANDA Host Setup
See docs/nanda-server-setup.md
for backend configuration and local registration of the NANDA Server.
Claude Desktop Setup
See docs/claude-desktop-setup.md
for guidance on configuring the local development environment and MCP integration.
These guides include all required steps, environment configurations, and usage notes to get up and running.
search_clinical_evidence
: A MCP tool for querying clinical evidence data that returns formatted reports.
The tool accepts the following optional parameters:
disease_name
(str): Filter by disease (e.g., "Lung Non-small Cell Carcinoma").therapy_name
(str): Filter by therapy or drug (e.g., "Cetuximab").molecular_profile_name
(str): Filter by gene or variant (e.g., "EGFR L858R").phenotype_name
(str): Filter by phenotype (e.g., "Chest Pain").evidence_type
(str): Filter by evidence type (e.g., "PREDICTIVE", "DIAGNOSTIC").evidence_direction
(str): Filter by evidence direction (e.g., "SUPPORTS").filter_strong_evidence
(bool): If True
, only includes evidence with a rating > 3 (max 5).The tool returns a formatted string with four sections:
This project is licensed under the MIT License - see the LICENSE file for details.
⚠️ This tool is intended exclusively for research purposes. It is not a substitute for professional medical advice, diagnosis, or treatment.
Discover shared experiences
Shared threads will appear here, showcasing real-world applications and insights from the community. Check back soon for updates!